GLTO galecto.com Net earnings per share for the last 12 months

Public company logo of Galecto, Inc. (GLTO)

Galecto, Inc. develops galectin inhibitors for the treatment of severe liver and lung pathologies, leveraging large-scale R&D investments. The company's biochemistry aims to stop tissue scarring in cancer and fibrosis. The current change in the rolling annual EPS on GURU.Markets indicates a pipeline revision stage, where -12.09 reflects the metric's baseline until new onco-molecules generate a commercial effect.

GLTO (Galecto Corporation) Net earnings per share (EPS TTM) history from 07/04/2022 to 03/10/2026

Analytical breakdowns and data insights for company Galecto Inc (GLTO)

- stock price and consensus target price:
Stock Price Galecto, Inc.|GLTO - Average Forecast Price
- market capitalization data:
Market Valuation Galecto, Inc.|GLTO - Aggregate Business Value
- balance sheet net asset value indicators:
Book Value per Share Galecto|GLTO - Book Capitalization|Market Capitalization to Book Value Ratio galecto.com|GLTO - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Galecto, Inc.|GLTO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Galecto Corp|GLTO - Company Debts|Debts to Book Capitalization Galecto, Inc.|GLTO - Long-Term Debt Volume|Company Short-Term Debt Galecto|Quick Liquidity galecto.com
- net income and valuation multiples indicators:
GLTO - Net Income|Projected Future Earnings Galecto, Inc.|GLTO - Market Cap to Net Income Ratio|Forward P/E Multiple Galecto|GLTO - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Galecto, Inc.|GLTO - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Galecto|GLTO - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth galecto.com|GLTO - Net earnings per share growth this year|Expected earnings per share growth for next year Galecto, Inc.
Fundamental company valuation:Galecto, Inc. (GLTO)
Mass-produced product of Galecto Corp

Galecto, Inc. (GLTO) focuses on capturing market share in metabolic pharma through the development of galectin inhibitors. Earnings per share over the trailing twelve months (EPS TTM) measures the final financial result allocated to a single security. This metric smooths out one-time market shocks, demonstrating the actual efficiency of the business. A slowdown in the trend line signals a decline in demand. By analyzing the EPS TTM dynamics of Galecto, Inc. (GLTO), an investor assesses the fundamental stability of the expansion strategy.

Competitors of Galecto, Inc.

Ascendis Pharma A/S - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months madrigalpharma.com|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Therapeutics|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (crinetics.com)|Earnings per share for the last twelve months NewAmsterdam Pharma Company N.V. NAMS|Soleno Therapeutics Inc (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx|Rezolute Inc (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Lexicon Pharma (LXRX)|Net earnings per share for the last 12 months MBX Corp MBX|Net earnings per share (EPS TTM) ALT (Altimmune, Inc.)|Net earnings per share for the trailing year aardvarktherapeutics.com|Sagimet Biosciences Inc. - Net earnings per share (EPS TTM)|BIOA - Net earnings per share (EPS TTM)|Biomea (BMEA) - Earnings per share for the last twelve months|QNCX (Quince Therapeutics, Inc.) - Earnings per share for the last twelve months|GUTS (Fractyl Health, Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months vTv Therapeutics Inc VTVT|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last 12 months pluri-biotech.com PLUR|Synlogic - Net earnings per share for the last 12 months|Earnings per share for the last four quarters LPCN (Lipocine Corporation)|MTNB - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Spruce Biosciences Inc.|CTCX (Carmell) - Net earnings per share for the last 12 months|Lumos Pharma Inc - Earnings per share for the trailing year|ONVO (Organovo Holdings Inc) - Net earnings per share (EPS TTM)|Radius Pharmaceuticals (RDUS) - Net earnings per share for the last four quarters